Compare INDI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | VALN |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 820.0M |
| IPO Year | N/A | 2021 |
| Metric | INDI | VALN |
|---|---|---|
| Price | $4.41 | $8.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.25 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 3.4M | 19.2K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $217,396,000.00 | $211,089,992.00 |
| Revenue This Year | $1.91 | $5.08 |
| Revenue Next Year | $30.15 | $12.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $1.53 | $3.62 |
| 52 Week High | $6.05 | $12.25 |
| Indicator | INDI | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 43.43 |
| Support Level | $3.44 | $8.62 |
| Resistance Level | $4.76 | $9.18 |
| Average True Range (ATR) | 0.27 | 0.29 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 78.26 | 14.73 |
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.